Title of Invention

NOVEL SULFONAMIDES

Abstract The present invention relates to a compounds of the formula Wherein R<sup>1</sup> signifies phenyl or phenyl substituted by halogen, C<sub>1</sub>-C<sub>7</sub>alkyl, C<sub>1</sub>-C<sub>7</sub>alkoxy, C<sub>1</sub>-C<sub>7</sub>alkylenedioxy, carboxyl, carboxyl or trifluoromethyl; or heterocyclyl selected from mono-or bicyclic, 5- and 6-membered heterocycles having oxygen, nitrogen or sulphur as the heteroatom. R<sup>2</sup> signifies tetrazolyl, C<sub>1</sub>-C<sub>7</sub>alkyl-substituted tetrazolyl, cyano, carboxy, C<sub>1</sub>-C<sub>7</sub>alkoxy- carbonyl, hydroxymethyl, formyl, carbamoyl, thiocarbamoyl, amidino or hydroxy- amidino; R<sup>3</sup> signifies a residue -O-(CR<sup>a</sup> R<sup>b</sup>) <sub>n</sub>-OR<sup>9</sup>; R<sup>4</sup> _R<sup>8</sup> signify hydrogen. C<sub>1</sub>-C<sub>7</sub>alkoxy or halogen; R<sup>9</sup> signifies hydrogen, benzyl, benzyl substituted in the phenyl ring by halogen. C<sub>1</sub>-C<sub>7</sub>- alkyl, C<sub>1</sub>-C<sub>7</sub>alkoxy, C<sub>1</sub>-C<sub>7</sub>alkylenedioxy. carboxyl or trifluoromethyl; or a residue- .C(O)NHRl<sup>10</sup>; R<sup>10</sup> signifies C<sub>1</sub>-C<sub>7</sub>alkyl, phenyl, phenyl substituted by halogen, C<sub>1</sub>-C<sub>7</sub>alkyl, C<sub>1</sub>-C<sub>7</sub>alkoxy. C<sub>1</sub>-C<sub>7</sub>alkyienedioxy, carboxyl or trifluoromethyl, pyridyl or pyridyl substituted by l or2 C<sub>1</sub>-C<sub>7</sub>alkyl groups; R<sup>a</sup> and R<sup>b</sup> signify hydrogen or C<sub>1</sub>-C7alkyl; N signifies 2, 3 or 4; and A and B signify CH; or one of the symbols A or B signifies nitrogen and the other signifies CH; and pharmaceutically usable salts of compounds of formula I, with the proviso that R<sup>2</sup> is not carboxy when A and Bare CH.
Full Text

The present invention is concerned with novel sulphonamides and their use as medicaments. In particular, the invention is concerned with novel compounds of the formula

wherein
R^ signifies aryl or heterocyclyl;
R2 signifies tetrazolyl, lower-alkyl-substituted
tetrazolyl, cyano, carboxy, lower-alkoxycarbonyl,
hydroxymethyl, formyl, carbamoyl, thiocarbamoyl,
amidino or hydroxyamidino;
R3 signifies a residue -O-(CRaRb)n-OR9;
R4-R8 signify hydrogen, lower-alkoxy or halogen;
R9 signifies hydrogen, aryl, lower-aralkyl, heterocyclyl
or a residue -C(O)NHR10;
R10 signifies lower-alkyl, phenyl, substituted phenyl,
pyridyl or substituted pyridyl;
Ra and Rb signify hydrogen or lower-alkyl;
n signifies 2, 3 or 4; and
A and B signify CH; or one of the symbols A or B signifies
nitrogen and the other signifies CH; or
R2 signifies hydrogen and one of the symbols A or B
signifies N-oxide (N-O) and the other signifies CH,
and pharmaceutically usable salts of compounds of formula I.
Examples of aryl residues are phenyl and substituted phenyl residues, with esp. halogen, lower-alkyl, lower-alkoxy, lower-alkylenedioxy, carboxyl and trifluoromethyl coming into consideration as substituents. Lower-aralkyl signifies lower alkyl residues substituted by aryl, e.g. phenyl or substituted phenyl, preferably benzyl. Examples of heterocyclyl residues are residues of mono- or bicyclic, 5- and 6-membered heterocycles

having oxygen, nitrogen or sulphur as the hetero atom, such as 2-and 3-furyl, 2-, 4- and 5-pyrimidinyl, 2-, 3- and 4-pyridyl, 1,2-and 1,4-diazinyl, 2- and 3-thienyl, oxazolyl, thiazolyl, imidaz-olyl, benzofuranyl, benzothienyl, purinyl, quinolyl, isoquinoly! and quinazolyl, which residues can be substituted, e.g. by 1 or 2 lower-alky! groups. Preferably, heterocyclyl is a pyrldyl residue or a substituted pyridyl residue.
The term "lower" used here denotes groups with 1 -7 C atoms, preferably 1-4 C atoms. Alkyl and alkoxy groups can be straight-chain or branched. Methyl, ethyl, propyl, isopropyl, butyl, sec. and tert.butyl are examples of such alkyl groups. Halogen denotes fluorine, chlorine, bromine and iodine, with chlorine being preferred.
A preferred group of compounds of formula I comprises those in which A and B are CH or one of the symbols A and B is nitrogen. R1 is preferably a phenyl residue, which is mono- or di-substituted, or a pyridyl residue, which is mono-substituted by alkyl, especially an alkyl-substituted 2-pyridyl residue. R2 is preferably a tetrazolyl residue. R3 is preferably -O(CH2)nOH, -O(CH2)nO-benzyl or -O(CH2)nOC(O)NHR10, in which R10 is pyridyl, especially 2-pyridyl. n is preferably 2. Of particular interest among these compounds are those in which R4 is lower-alkoxy and R5-R8 are hydrogen; or R4 is halogen, R7 is lower-alkoxy and R5, R6 and R8 are hydrogen; A is nitrogen and B is CH.
The compounds of formula I can be manufactured by
a) reacting a compound of formula II


wherein R12 is 3- or 4-cyanophenyl or 2- or 4-pyridyl N-oxide and Hal is halogen and the remaining symbols have the significance set forth above, with a compound of the formula MO-(CRaRb)n-OR91, wherein M is an alkali metal and R91 is hydrogen, aryl, lower-aralkyl or heterocyclyl and Ra, Rb and n have the significance set forth above; or
b) reacting a compound of formula III

wherein R1 1 is 2- or 4-pyridyl N-oxide and the remaining symbols have the significance set forth above, with a trialkylsilyl cyanide and a trialkylamine; or
c) reacting a compound of formula I in which R2 is cyano and the remaining symbols have the significance set forth above with an azide in the presence of an aprotic Lewis acid; or
d) converting a compound of formula I in which R2 is cyano and the remaining symbols have the significance set forth above with an alkali metal alcoholate and thereafter with hydrazine into the corresponding amidrazone and treating this with a nitrite and an acid; or
e) reacting a compound of formula I in which R9 is hydrogen with an isocyanate of the formula R10NCO; or
f) transforming the cyano group in a compound of formula I in which R2 is cyano and the remaining symbols have the significance set forth above into an amidino, carbamoyl, thiocarbamoyl, lower-alkoxycarbonyl, carboxy, hydroxymethyl, formyl or hydroxyamidino group; or

g) alkylating the tetrazolyl group in a compound of formula I in which R2 is tetrazolyl and R9 is aryl, lower-aralkyl or hetero-cyclyl and cleaving off a hydroxy protecting group from the reaction product;
and, if desired, converting a compound of formula I obtained into a salt.
The reaction of a compound of formula II with a compound of the formula MO(CRaRb)nOR91 (process variant a) is conveniently carried out in a glycol corresponding to this compound as the solvent, e.g. in ethylene glycol when n = 2 and Ra and Rb are hydrogen. The alkali metal M is preferably sodium and Hal is preferably chlorine. The reaction is conveniently carried out while heating, e.g. to 40-100oC. According to this process variant there are obtained compounds of formula I in which R2 signifies cyano and A and B signify CH; or R2 signifies hydrogen and one of the symbols A or B signifies N-oxide and the other signifies CH, and R9 is a residue R91 as defined above, and the remaining symbols have the given significance.
In process variant b) a N-oxide of formula II is preferably reacted with trimethylsilyl cyanide and triethylamine. The reaction is conveniently carried out in acetonitrile while heating to the reflux temperature of the reaction mixture. According to this process variant there are obtained compounds of formula I in which R2 signifies cyano and one of the symbols A or B signifies nitrogen and the other signifies CH and the remaining symbols have the given significance.
In the reaction according to process variant c) there can be used as the azide e.g. sodium azide, guanidinium azide or trimethylsilyl azide. Ammonium salts, e.g. ammonium chloride, can be used as Lewis acids. The reaction can be carried out in an aprotic, polar solvent such as dimethylformamide or dimethyl sulphoxide, conveniently while heating, e.g. to a temperature of 60-100°C.

The reaction of a compound of formula I in which R2 is cyano with hydrazine according to process variant d) proceeds via the iminoether, from which the amidrazone, i.e. a compound corresponding to formula I with R2 = -CH(NH)NHNH2, is obtained with excess hydrazine. The amidrazone is converted by nitro-sation into an iminoazide which cyclizes spontaneously to the tetrazole. According to process variants c) and d) there are obtained compounds of formula I in which R2 signifies tetrazolyl and the remaining symbols have the given significance.
The reaction in accordance with process variant e) can be effected in a manner known per se for the preparation of carbamates from alcohols and isocyanates, e.g. in in a suitable anhydrous organic solvent, e.g. a hydrocarbon such as toluene, conveniently while heating. The isocyanate can be generated in situ, e.g. from an azide of the formula R10CON3 by thermal rearrangement. According to this process variant there are obtained compounds of formula I in which R9 signifies a residue -C(O)NHR10 and the remaining symbols have the given significance.
The transformation of a cyano group R2 in a compound of formula I into an amidino, carbamoyl, thiocarbamoyl, lower-alkoxycarbonyl, carboxy, hydroxymethyl, formyl or hydroxy-amidino group in accordance with process variant f) can be effected in a manner known per se for such transformations. For example, the cyano group can be converted by treatment with alkali alcoholate, e.g. with sodium methylate in methanol, into an iminoether (i.e., the group C(NH)0CH3) which can be converted in situ by treatment with hydrochloric acid into an alkyl carboxylate (e.g. the group -COOCH3), which can be saponified to the carbox-ylic acid by treatment with alcoholic alkali. Alternatively, the iminoether, obtained in situ, can be transformed by treatment with ammonium chloride in methanol into the corresponding amidino compound (R2 = amidino) and this can be transformed by treatment with aqueous alkali and subsequent acidification into the corresponding carbamoyl compound (R2 = -C(O)NH2)). By treatment of the iminoether, obtained in situ, with hydroxyl-

amine and aqueous sodium acetate solution there can be obtained the corresponding hydroxyamidino compounds (R2 = -C(NH)NHOH). A carboxy group can be reduced by treatment with reducing agents such as sodium dihydro-bis-(2-methoxyethoxy)aluminate in toluene to the hydroxymethyl group and this can be oxidized to the formyl group by treatment with oxidizing agents such as manganese dioxide. In these reaction sequences R3 should not contain a hydroxy group, i.e. R9 should not represent hydrogen, but should represent e.g. benzyl.
The alkylation of a compound of formula I in accordance with process variant g) can be carried out in a manner known per se, e.g. by treatment with a lower-alkyl halide in the presence of a base such as K tert.-butylate in tetrahydrofuran, whereby a thus-obtained mixture of 1- and 2-lower-alkyl-tetrazolyl compounds of formula I can be separated in a manner known per se, e.g. by chromatography. Suitable hydroxy protecting groups are e.g. alkylsilyl protecting groups such as dimethyl-tert-butylsilyl and tetrahydropyranyl, which can be introduced and cleaved off from the reaction product in a manner known per se. According to process variant g) there are accordingly obtained compounds of formula I In which R2 represents a lower-alkyl-tetrazolyl residue and R9 represents hydrogen.
The compounds of formula I which contain a carboxy or tetrazolyl group can be converted in a manner known per se into pharmaceutically usable salts, e.g. alkali salts such as Na and K salts or alkaline earth metal salts such as Ca or Mg salts or salts with amines such as monoethanolamine.
The compounds which are used as starting materials, insofar as they are not known or their preparation is described hereinafter, can be prepared in analogy to known methods or to methods described below.
The compounds of formula I given above are endothelin receptor inhibitors. They can therefore be used for the treatment of disorders which are associated with endothelin activities,

especially circulatory disorders such as hypertension, ischaemia, vasospasms and angina pectoris.
The inhibitory activity of the compounds of formula I on endothelin receptors can be demonstrated using the test procedures described hereinafter:
Inhibition of endothelin binding to recombinant ETA receptors
A cDNA coding for human ETA receptors of human placenta was cloned (M. Adachi, Y.-Y. Yang, Y. Furuichi and C. Miyamoto, BBRC 180, 1265-1272) and expressed in the baculovirus-insect cell system. Baculovirus-infected insect cells from a 23 I fermenter are centrifuged off (3000 x g, 15 minutes, 4oC) 60 hours after the infection, re-suspended in Tris buffer (5 mM, pH 7.4, 1 mM MgCl2) and again centrifuged. After a further re-suspension and centrifugation the cells are suspended in 800 ml of the same buffer and freeze-dried at -120oC. The cells disintegrate when the suspension in this hypotonic buffer mixture is thawed. After a repeated freeze-drying/thawing cycle the suspension is homogenized and centrifuged (25000 x g, 15 minutes, 4oC). After suspension in Tris buffer (75 mM, pH 7.4, 25 mM MgCl2, 250 mM sucrose) 1 ml aliquots (protein content about 3.5 mg/ml) are stored at -85°C.
For the binding assay, the freeze-dried membrane preparations are thawed and, after centrifugation at 20°C and 25000 g for 10 minutes, re-suspended in assay buffer (50 mM Tris buffer, pH 7.4, containing 25 mM MnClz, 1 mM EDTA and 0.5% bovine serum albumin). 100µl of this membrane suspension containing 70 µg of protein are incubated with 50 µl of 1251.
endothelin (specific activity 2200 Ci/mMol) in assay buffer (25000 cpm, final concentration 20 pM) and 100 µl of assay
buffer containing varying concentrations of test compound. The incubation is carried out at 20°C for 2 hours or at 4oC for 24 hours. The separation of free and membrane-bound radioligands is carried out by filtration over a glass fibre filter. The inhibitory activity of compounds of formula I determined in this

test procedure is given in Table 1 as the IC50, i.e. as the concentration [nM] which Is required to Inhibit 50% of the specific binding of 125|-endothelln.

11. Inhibition of endothelin-induced contractions in isolated rat aorta rings
Rings with a length of 5 mm were cut out from the thorax aorta of adult Wistar-Kyoto rats. The endothelium was removed by lightly rubbing the internal surface. Each ring was immersed at 37°C in 10 ml of Krebs-Henseleit solution in an isolated bath while gassing with 95% O2 and 5% CO2. The isometric stretching of the rings was measured. The rings were stretched to a pretension of 3 g. After incubation for 10 minutes with the test compound or vehicle cumulative dosages of endothelin-1 were added. The activity of the test compound was ascertained by the observed shift to the right of the dosage-activity curve of endothelin-1 in the presence of different concentrations of antagonist. This shift to the right (or "dose ratio", DR) corresponds to the quotient from the EC50 values of endothelin-1 in the presence and in the absence of antagonist, with the EC50 value denoting the endothelin concentration required for a half-maximum contraction.
The corresponding pA2 value, which is a measure of the activity of the test compound, was calculated using a computer programme according to the following equation from the "dose ratio" DR for each individual dosage-activity curve.

pA2 = log(DR-1)-log(antagonist-concentration)
The EC50 of endothelin in the absence of test compounds is 0.3 nM.
The pA2 values obtained with compounds of formula I are given in Table 2.

On the basis of their capability of inhibiting endothelin binding, the compounds of formula I can be used as medicaments for the treatment of disorders which are associated with vasoconstriction of Increasing frequencies. Examples of such disorders are high blood pressure, coronary disorders, cardiac insufficiency, renal and myocardial ischaemia, renal insufficiency, dialysis, cerebral ischaemia, cerebral infarct, migraine, subarachnoid haemorrhage, Raynaud syndrome and pulmonary high pressure. They can also be used in atherosclerosis, the prevention of restenosis after balloon-induced vascular dilation, inflammations, gastric and duodenal ulcers, ulcus cruris, gram-negative sepsis, shock, glomerulonephtritis, renal colic, glaucoma, asthma, in the therapy and prophylaxis of diabetic complications and complications in the administration of cyclosporin, as well as other disorders associated with endothelin activities.
The compounds of formula I can be administered orally, rectally, parentally, e.g. intravenously, intramuscularly.

subcutaneously, intrathecally or transdermally; or sublingually or as opththalmological preparations, or as an areosol. Capsules, tablets, suspensions or solutions for oral administration, suppositories, injection solutions, eye drops, salves or spray solutions are examples of administration forms.
Intravenous, intramuscular or oral administration is a preferred form of use. The dosages in which the compounds of formula I are administered in effective amounts depend on the nature of the specific active ingredient, the age and the requirements of the patient and the mode of administration. In general, dosages of about 0.1-100 mg/kg body weight per day come into consideration. The preparations containing the compounds of formula I can contain inert or also pharmacodynamically active additives. Tablets or granulates e.g. can contain a series of binders, fillers, carriers or diluents. Liquid preparations can be present, for example, in the form of a sterile water-miscible solution. Capsules can contain a filler or thickener in addition to the active ingredient. Furthermore, flavour-improving additives as well as substances usually used as preserving, stabilizing, moisture-retaining and emulsifying agents as well as salts for varying the osmotic pressure, buffers and other additives can also be present.
The previously mentioned carrier materials and diluents can comprise organic or inorganic substances, e.g. water, gelatine, lactose, starch, magnesium stearate, talc, gum arable, poly-alkylene glycols and the like. It is a prerequisite that all adjuvants used in the manufacture of the preparations are nontoxic.
The following Examples illustrate the Invention in more detail. DMF denotes dimethylformamide, THF denotes tetrahydro-furan and EtOAc denotes ethyl acetate.

Example 1
a) 200 ml of dimethoxyethane and 110.9 g of 4-[4-(4-tert-
butyl-phenyl-sulphonylamino)-6-chloro-5-(2-methoxy-phenoxy)-
pyrimidin-2-yl]-pyrldine 1-oxide are added all at once to a
solution of 23.80 g of sodium in 660 ml of ethylene glycol. The
solution is heated at 90oC for 20 hours while stirring, thereafter
cooled, poured into 2500 ml of H2O and thereafter treated with
CH3COOH to pH 5. The mixture is extracted three times with
EtOAc, the organic phase is washed with H2O, dried with Na2SO4
and evaporated under reduced pressure. The residue is recrystall-
ized from CH3CN and thereafter twice from a mixture of acetone
and CH3CN. There is thus obtained 4-[4-(4-tert-butyl-phenyl-
sulphonylamino)-6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-
pyrimidin-2-yl]-pyridine 1 -oxide.
Preparation of the starting material:
b) 53.1 g of 4-cyano-pyridine (98%) are added all at once to a
solution of 1.15 g of sodium in 200 ml of abs. MeOH. After
6 hours 29.5 g of NH4C! are added while stirring vigorously. The mixture is stirred at room temperature overnight. 600 ml of ether are added thereto, whereupon the precipitate is filtered off under suction and thereafter dried at 50°C under reduced pressure. There is thus obtained 4-amidino-pyridine hydrochloride (decomposition point 245-2470C).
c) 112.9 g of diethyl (2-methoxyphenoxy)malonate are added
dropwise within 30 minutes to a solution of 27.60 g of sodium
in 400 ml of MeOH. Thereafter, 74.86 g of the amidine hydro
chloride obtained in b) are added all at once. The mixture is
stirred at room temperature overnight and evaporated at 50°C
under reduced pressure. The residue is treated with 500 ml of
ether and filtered off under suction. The filter cake is dissolved
in 1000 ml of H2O and treated little by little with 50 ml of
CH3COOH. The precipitate is filtered off under suction, washed
with 400 ml of H2O and dried at 80°C under reduced pressure.

There is thus obtained 5-(2-methoxy-phenoxy)-2-(pyridin-4-yl)-pyrimidine-4,6-diol (or tautomer), melting point above 250oC.
d) A suspension of 154.6 g of 5-(2-methoxy-phenoxy)-2-(pyridin-4-yl)-pyrimidine-4,6-diol (or tautonner) in 280 mi of POCI3 is heated at 120oC in an oil bath for 24 hours while stirring vigorously. The reaction mixture changes gradually into a dark brown liquid which is evaporated under reduced pressure and thereafter taken up three times with 500 ml of toluene and evaporated. The residue is dissolved in 1000 ml of CH2CI2, treated with ice and H2O and thereafter adjusted with 3N NaOH until the aqueous phase has pH 8. The organic phase is separated and the aqueous phase is extracted twice with CH2CI2. The combined CH2CI2 extracts are dried with MgSO4, evaporated to half of the volume, treated with 1000 ml of acetone and the CH2CI2 remaining is distilled off at normal pressure. After standing in a refrigerator for 2 hours the crystals are filtered off under suction and dried at 50°C overnight. There is thus obtained 4,6-dichIoro-5-(2-methoxy-phenoxy)-2-pyridin-4-yl)-pyrimidine, melting point 178-180°C.
e) A solution of 17.4 g of 4,6-dichloro-5-(2-methoxy-phenoxy)-2-pyridin-4-yl)-pyrimidine in 100 ml of CH3CN is boiled at reflux for 3 hours with 15 ml of a 32% peracetic acid solution, thereafter cooled and stored in a refrigerator overnight. The crystals are filtered off under suction and dried at 50°C under reduced pressure. There is thus obtained 4-[4,6-dichloro-5-(2-methoxy-phenoxy)-pyrimidin-2-yl]-pyridine 1 -oxide, melting point 189-190°C.
f) A solution of 36.4 g of 4-[4,6-dichloro-5-(2-methoxy-phenoxy)-pyrimidin-2-yl]-pyridine 1-oxide and 52.8 g of p-tert-butylphenyl-sulphonamide potassium in 150 ml of abs. DMF is stirred at room temperature for 24 hours. Thereafter, it is poured into a mixture of 1 500 ml of H2O and 1000 ml of ether while stirring mechanically, whereby a precipitate forms. The suspension is adjusted to pH 5 with CH3COOH, suction filtered, the crystals are washed with cold water and thereafter with

ether and dried at 50oC. There is thus obtained 4-[4-(4-tert-butyl-phenylsulphonylamino)-6-chloro-5-(2-methoxy-phenoxy)-pyrimidin-2-yl]-pyridine 1-oxide as a colourless material of melting point 247-2490C.
Example 2
A solution of 78.45 g of 4-[4-(4-tert-butyl-phenyl-sulphonylamino)-6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-pyrimidin-2-yl]-pyridine 1-oxide, 122.5 g of trimethylsilyl cyanide, 127.8 g of triethylamine and 1200 ml of CH3CN is boiled at reflux for 20 hours and thereafter evaporated under reduced pressure. The oily residue is taken up in 1000 ml of EtOAc and the solution is washed with CH3COOH:H2O 9:1 and then with H2O. The EtOAc extracts are dried with Na2SO4. After evaporation of the solvent the residue is taken up in a mixture of CH3CN and CF3COOH (20:1), whereby a crystalline precipitate separates. There is thus obtained 4-tert-butyl-N-[2-(2-cyano-pyridin-4-yl)-6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-pyrimidin-4-yl]-benzenesulphonamide of melting point 176-179°C.
Example 3
A suspension of 50.0 g of 4-tert-butyl-N-[2-(2-cyano-pyridin-4-yl)-6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-pyrimidin-4-yl]-benzenesulphonamide, 46.33 g of NH4CI and 56.47 g of NaN3 in 1600 ml of DMF is heated to 70°C for 24 hours while stirring vigorously. The majority of the solvent is distilled off under reduced pressure, the residue is dissolved in H2O, the solution is extracted four times at pH 6.5 with ether, thereafter treated with CH3COOH to pH = 4.5 and extracted with EtOAc. After working up there is obtained a residue which is treated with ether and filtered off under suction therefrom. There is thus obtained 4-tert-butyl-N-[6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(2-1H-tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4-yl]-benzenesulphonamide, melting point 225-227°C.

Example 4
a) To a solution, heated to 90°C, of 46.0 g of 4-tert-butyl-N-
[6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(2-lH-
tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4-yl]-benzenesulphon-
amide in 600 ml of abs. dioxan is added dropwise within
60 minutes while stirring a cold solution of 22.0 g of 2-pyridyl-carbonyl azide in 200 ml of dioxan. After 4 hours the solvent is evaporated under reduced pressure, the residue is taken up in 300 ml of EtOAc and left to stand at room temperature overnight. The crystalline mass is filtered off under suction and washed with EtOAc. After repeated recrystallization from tetrahydro-furan and EtOAc and drying under reduced pressure firstly at 450C for 3 days and thereafter at 65°C for a further 2 days there is obtained 2-[6-(4-tert-butyl-phenylsulphonylamino)-5-(2-methoxy-phenoxy)-2-(2-1H-tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4-yl-oxy]-ethyl pyridin-2-ylcarbamate, melting point from 214°C with very slow decomposition.
b) The 2-pyridyl-carbonyI azide used as the starting material
can be prepared as follows:
A solution of 53.9 g of 2-picolinic acid in 330 ml of abs. DMF and 61.2 ml of triethylamine is treated dropwise within 30 minutes at 10°C with 99.7 ml of diphenylphosphoryl azide. After 2 hours at room temperature the solution is evaporated for the most part at 30oC under reduced pressure, the oily residue is treated with 200 ml of a 5% sodium bicarbonate solution and exhaustively extracted with ether. The ethereal extracts are combined, dried with MgSO4 and evaporated at room temperature under reduced pressure. The yellowish oily residue is cooled in an ice bath at 0-5°C and the crystals are washed at -20oC with a 1:1 mixture of ether and hexane. There is thus obtained 2-pyridyl-carbonyl azide as colourless crystals of melting point 39-41 oC.

Example 5
A solution of 47.8 g of 2-[6-(4-tert-butyl-phenylsulphonyl-amino)-5-(2-methoxy-phenoxy)-2-(2-lH-tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4-yloxy]-ethyl pyridin-2-ylcarbamate in 500 ml of abs. THF is treated dropwise with a cold solution of 2.8 g of sodium in 50 ml of methanol, whereby there forms gradually a solid precipitate which, after stirring at room temperature for
1 hour, is filtered off under suction, dried under greatly reduced
pressure at 35°C for 3 days and thereafter at 50oC for 2 days.
There is thus obtained the bis-sodium salt, decomposition point
above 250oC.
Example 6
The same tetrazole as in Example 3 is obtained starting from the same starting material as in Example 3 in a one-pot reaction (3 steps) under the following conditions:
2.4 ml of a 1 .ON sodium methylate solution are added at room temperature to a suspension of 1.15 g (2 mmol) of 4-tert-butyl-N-[2-(2-cyano-pyridin-4-yl)-6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-pyrimidin-4-yl]-benzenesulphonamide in 50 ml of abs. MeOH. The clear yellowish solution which results therefrom is held at 40oC for 3 days.
The solution of the iminoether is slowly added dropwise at room temperature within 30 minutes to a suspension of 302 mg (4.4 mmol) of HzN-NHz-HCI in 10 ml of abs. MeOH, whereby a crystalline precipitate separates gradually. The suspension is cooled to 2°C while stirring further and treated with 15 ml of l.ON HCI. The clear yellowish solution (pH = 1.7) is treated dropwise with a solution of 800 mg (11.6 mmol) of NaNOz in 10 ml of H2O in such a manner that the temperature does not exceed 5°C (pH 2.7). After 1 hour a further 2 ml of 1N HCI are added and then a solution of 200 mg (2.9 mmol) of NaNOz in 2 ml of H2O is added. The solution is left at room temperature for
2 hours, the MeOH is evaporated under reduced pressure and the

suspension remaining behind is extracted with EtOAc. The combined EtOAc solutions are firstly washed twice with H2O and thereafter carefully extracted with a 0.5N NaHCO3-H2O solution. The combined aqueous (NaHCO3) solutions are carefully treated with 3N HCI (to pH = 2) and the suspension is extracted with EtOAc as usual. After evaporation of the solvent under reduced pressure there is obtained a crystalline residue which is identical with the product obtained in Example 3.
Example 7
a) In analogy to Example la), from N-[6-chloro-5-(2-methoxy-phenoxy)-2-(l-oxy-pyridin-4-yl)-pyrimidin-4-yl]-benzenesulphonamide and Na glycolate in ethylene glycol there is obtained N-[6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(1 -oxy-pyridin-4-yl)-pyrimidin-4-yl]-benzenesulphonamide, melting point n 0-n 2°C (from EtOAc).
b) In analogy to Example 2, from N-[6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(l-oxy-pyridin-4-yl)-pyrimldin-4-yl]-benzenesulphonamide there is obtained N-[2-(2-cyano-pyridin-4-yl)-6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-pyrlmidin-4-yl]-benzenesulphonamide.
Example 8
a) In analogy to Example la), from N-[6-chloro-5-(2-methoxy-phenoxy)-2-(l-oxy-pyridin-4-yl)-pyrimidin-4-yl]-4-methyl-benzenesulphonamide there is obtained N-[6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(l-oxy-pyridin-4-yl)-pyrimidin-4-yl]-4-methyl-benzenesulphonamide, melting point 172-173°C (from EtOAc).
b) In analogy to Example 2, from N-[6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(l-oxy-pyridin-4-yl)-pyrimidin-4-yl]-4-methyl-benzenesulphonamide there is obtained N-[2-(2-cyano-pyridin-4-yl)-6-(2-hydroxy-ethoxy)-5-(2-

methoxy-phenoxy)-pyrimidin-4-yl]-4-methyl-benzenesulphon-amide.
Example 9
a) In analogy to Example 1a), from N-[6-chloro-5-(2-methoxy-phenoxy)-2-(1-oxy-pyridin-4-yl)-pyrimidin-4-yl]-4-methoxy-benzenesulphonamide there is obtained N-[6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(l-oxy-pyridin-4-yl)-pyrimidin-4-yl]-4-methoxy-benzenesuiphonamide as a white solid.
b) In analogy to Example 2, from N-[6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(1-oxy-pyridin-4-yl)-pyrimidin-4-yl]-4-methoxy-benzenesulphonic acid there is obtained N-[2-(2-cyano-pyridin-4-yl)-6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-pyrimidin-4-yl]-4-methoxy-benzene-sulphonamide.
Example 10
a) In analogy to Example 1a), from N-[6-chloro-5-(2-methoxy-phenoxy)-2-(1-oxy-pyridin-4-yl)-pyrimidin-4-yl]-4-methylsulphanyl-benzenesulphonamide there is obtained N-[6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-( 1 -oxy-pyridin-4-yl)-pyrimidin-4-yl]-4-methylsulphanyl-benzenesulphonamide, melting point 146-150°C (from acetonitrile).
b) In analogy to Example 2, from N-[6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(l-oxy-pyridin-4-yl)-pyrimidin-4-yl]-4-methylsulphanyl-benzenesulphonamide there is obtained N-[2-(2-cyano-pyridin-4-yl)-6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-pyrimidin-4-yl]-4-methylsulphanyl-benzenesulphonamide.

Example 11
a) In analogy to Example 1a), from 1,3-benzodioxol-5-sulphonic acid 6-chloro-5-(2-methoxy-phenoxy)-2-(1-oxy-pyridin-4-yl)-pyrimidin-4-ylamide there is obtained 1,3-benzodioxol-5-sulphonic acid 6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(1-oxy-pyridin-4-yl)-pyrimidin-4-ylamide, melting point 174-175°C (from acetonitrile).
b) In analogy to Example 2, from 1,3-benzodioxol-5-sulphonic add 6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(1-oxy-pyridin-4-yl)-pyrimidin-4-ylamide there is obtained 1,3-benzodioxol-5-sulphonic acid 2-(2-cyano-pyridin-4-yl)-6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-pyrimidin-4-ylamide.
Example 12
a) In analogy to Example 1a), from N-[6-chloro-5-(2-methoxy-phenoxy)-2-(1-oxy-pyridin-4-yl)-pyrimidin-4-yl]-3,4-dimethoxy-benzenesulphonamide there is obtained N-[6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-( 1 -oxy-pyridin-4-yl)-pyrimidin-4-yl]-3,4-dimethoxy-benzenesulphonamide, melting point 189-191 oC (from EtOAc).
b) In analogy to Example 2, from N-[6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(1-oxy-pyridin-4-yl)-pyrimidin-4-yl]-3,4-dimethoxy-benzenesulphonamide there is obtained N-[2-(2-cyano-pyridin-4-yl)-6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-pyrimidin-4-yl]-3,4-dimethoxy-benzenesulphonamide.
Example 13
a) In analogy to Example 1a), from N-[6-chIoro-5-(2-methoxy-phenoxy)-2-(1-oxy-pyridin-4-yl)-pyrimidin-4-yl]-2,5-dimethoxy-benzenesulphonamide there is obtained N-[6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(1-oxy-pyridin-4-

yl)-pyrimidin-4-yl]-2,5-dimethoxy-benzenesulphonamide as a white solid.
b) In analogy to Example 2, from N-[6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(1-oxy-pyrldin-4-yl)-pyrimidin-4-yl]-2,5-dimethoxy-benzenesulphonamide there is obtained N-[2-(2-cyano-pyridin-4-yl)-6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-pyrimidin-4-yl]-2,5-dimethoxy-benzenesulphonamide.
Example 14
a) In analogy to Example 1a), from pyridine-3-sulphonic acid 6-chloro-5-(2-methoxy-phenoxy)-2-(l-oxy-pyridin-4-yl)-pyrimidin-4-ylamide there is obtained pyridine-3-sulphonic acid 6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(l-oxy-pyridin-4-yl)-pyrimidin-4-ylamide, melting point 227-228°C(from EtOAc).
b) In analogy to Example 2, from pyridine-3-sulphonic acid 6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(1 -oxy-pyridin-4-yl)-pyrimidin-4-ylamide there is obtained pyridine-3-sulphonic acid 2-(2-cyano-pyridin-4-yl)-6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-pyrimidin-4-ylamide.
Example 15
a) In analogy to Example 1a), from 5-methyl-pyrldine-2-sulphonic acid 6-chloro-5-(2-methoxy-phenoxy)-2-(1-oxy-pyridin-4-yl)-pyrimidin-4-ylamide there is obtained 5-methyl-pyridine-2-sulphonic acid 6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(1 -oxy-pyridin-4-yl)-pyrimidin-4-ylamide, melting point 188-190°C (from acetonitrile).
b) In analogy to Example 2, from 5-methyl-pyridine-2-sulphonic acid 6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(1-oxy-pyridin-4-yl)-pyrimidin-4-yIamide there is obtained 5-methyl-pyridine-2-sulphonic acid 2-(2-cyano-pyridin-4-yl)-6-

(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-pyrimidin-4-ylamide.
Example 16
a) In analogy to Example 1a), from 5-isopropyl-pyridine-2-sulphonic acid 6-chloro-5-(2-methoxy-phenoxy)-2-(1-oxy-pyridin-4-yl)-pyrimidin-4-ylamide there is obtained 5-iso-propyl-pyridine-2-sulphonic acid 6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(1-oxy-pyridin-4-yl)-pyrimidin-4-ylamide, melting point 140-141 °C (from EtOAc).
b) In analogy to Example 2, from 5-isopropyl-pyridine-2-sulphonic acid 6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(l-oxy-pyridin-4-yl)-pyrimidin-4-ylamide there is obtained 5-isopropyl-pyridine-2-sulphonic acid 2-(2-cyano-pyridin-4-yl)-6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-pyrimidin-4-ylamide.
Example 17
a) In analogy to Example 1a), from 4-tert-butyl-N-[6-chloro-5-(2-chloro)-5-methoxy-phenoxy)-2-(1-oxy-pyridin-4-yl)-pyrimidin-4-yl]-benzenesulphonamide there is obtained 4-tert-butyl-N-[5-(2-chlor-5-methoxy-phenoxy)-6-(2-hydroxy-ethoxy)-2-(l-oxy-pyridin-4-yl)-pyrimidin-4-yl]-benzene-sulphonamide, melting point 228-230°C (from EtOAc).
b) In analogy to Example 2, from 4-tert-butyl-N-[5-(2-chloro-5-methoxy-phenoxy)-6-(2-hydroxy-ethoxy)-2-( 1 -oxy-pyridin-4-yl)-pyrimidin-4-yl]-benzenesulphonamide there is obtained 4-tert-butyl-N-[5-(2-chloro-5-methoxy-phenoxy)-2-(2-cyano-pyridin-4-yl)-6-(2-hydroxy-ethoxy)-pyrimidin-4-yl]-benzenesulphonamide.

Example 18
a) In analogy to Example 1a), from l,3-benzodioxol-4-sulphonic acid 6-chloro-5-(2-chloro-5-methoxy-phenoxy)-2-(l-oxy-pyridin-4-yl)-pyrimidin-4-ylamide there is obtained 1,3-benzodioxol-4-sulphonic acid 5-(2-chloro-5-methoxy-phenoxy)-6-(2-hydroxy-ethoxy)-2-(1-oxy-pyridin-4-yl)-pyrimidin-4-ylamide, melting point 208-21 0°C (from EtOAc).
b) In analogy to Example 2, from 1,3-benzodioxol-4-sulphonic acid 5-(2-chloro-5-methoxy-phenoxy)-6-(2-hydroxy-ethoxy)-2-(l-oxy-pyridin-4-yl)-pyrimidin-4-ylamide there is obtained l,3-benzodioxol-5-sulphonic acid 5-(2-chloro-5-methoxy-phenoxy)-2-(2-cyano-pyridin-4-yl)-6-(2-hydroxy-ethoxy)-pyrimidin-4-ylamide.
Example 19
a) In analogy to Example 1a), from 5-isopropyl-pyridine-2-sulphonic acid-6-chloro-5-(2-chloro-5-methoxy-phenoxy)-2-(1-oxy-pyridin-4-yl)-pyrimidin-4-ylamide there is obtained 5-1 isopropyl-pyridine-2-sulphonic acid-5-(2-chloro-5-methoxy-phenoxy)-6-(2-hydroxy-ethoxy)-2-(1-oxy-pyridin-4-yl)-pyrimidin-4-ylamide, melting point 204-206°C (from EtOAc).
b) In analogy to Example 2 from 5-isopropyl-pyridine-2-sulphonic acid 5-(2-chloro-5-methoxy-phenoxy)-6-(2-hydroxy-ethoxy)-2-(1-oxy-pyridin-4-yl)-pyrimidin-4-ylamide there is obtained 5-isopropyl-pyridine-2-sulphonic acid 5-(2-chloro-5-methoxy-phenoxy)-2-(2-cyano-pyridin-4-yl)-6-(2-hydroxy-ethoxy)-pyrimidin-4-ylamide.
Example 20
a) In analogy to Example 1a), from 2-[4-(4-tert-butyl-phenylsulphonylamino)-6-chloro-5-(2-methoxy-phenoxy)-pyrimidin-2-yl]-pyridine 1-oxide there is obtained 2-[4-(4-tert-butyl-phenylsulphonylamino)-6-(2-hydroxy-ethoxy)-5-(2-

methoxy-phenoxy)-pyrimiclin-2-yl]-pyridine 1-oxide as an amorphous substance.
b) In analogy to Example 2 from 2-[4-(4-tert-butyl-phenylsulphonylamino)-6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-pyrimidin-2-yl]-pyridine 1-oxide there is obtained 4-tert-butyl-N-[2-(6-cyano-pyridin-2-yl)-6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-pyrimidin-4-yI]-benzenesulphonamide.
Example 21
In analogy to Example 3, from N-[2-(2-cyano-pyridin-4-yl)-6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-pyrimidin-4-yl]-benzenesulphonamide there is obtained N-[6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(2-1H-tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4-yl]-benzenesulphonamide as a white substance of melting point 205-207°C from acetonitrile.
Example 22
In analogy to Example 3, from N-[2-(2-cyano-pyridin-4-yl)-6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-pyrimidin-4-yl]-4-methyl-benzenesulphonamide there is obtained N-[6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(2-1H-tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4-yl]-4-methyl-benzenesulphonamide as a white substance of melting point 214-216°C from CH3CN.
Example 23
In analogy to Example 3, from N-[2-(2-cyano-pyridin-4-yl)-6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-pyrimidin-4-yl]-4-methoxy-benzenesulphonamide there is obtained N-[6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(2-1H-tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4-yl]-4-methoxy-benzenesulphonamide as a white substance of melting point 218-220°C from acetonitrile.

Example 24
In analogy to Example 3, from N-[2-(2-cyano-pyridin-4-yl)-6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-pyrimiclin-4-yl]-4-methylsulphanyl-benzenesulphonamide there is obtained N-[6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(2-1H-tetra2ol-5-yl-pyridin-4-yl)-pyrimidin-4-yl]-4-methylsulphanyl-benzene-sulphonamide as a white substance.
Example 25
In analogy to Example 3, from 1,3-benzodioxol-5-sulphonic acid 2-(2-cyano-pyridin-4-yl)-6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-pyrimidin-4-ylamid there is obtained 1,3-benzodioxol-5-sulphonic acid 6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(2-1H-tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4-ylamide as a white substance of melting point 227-229°C from CH3CN.
Example 26
In analogy to Example 3, from N-[2-(2-cyano-pyridin-4-yl)-6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-pyrimidin-4-yl]-3,4-dimethoxy-benzenesulphonamide there is obtained N-[6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(2-1H-tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4-yl]-3,4-dimethoxy-benzenesulphon-amide as a white substance of melting point 224-225°C from acetonitrile.
Exgmple 27
In analogy to Example 3, from N-[2-(2-cyano-pyridin-4-yl)-6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-pyrimidin-4-yl]-2,5-dimethoxy-benzenesulphonamide there is obtained N-[6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(2-1H-tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4-yl]-2,5-dimethoxy-benzenesulphon-amide as a white substance.

Example 28
In analogy to Example 3, from pyridine-3-sulphonic acid 2-(2-cyano-pyridin-4-yl)-6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-pyrimidin-4-ylamide there is obtained pyridine-3-sulphonic acid 6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(2-1H-tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4-ylamide as a white substance.
Example 29
In analogy to Example 3, from 5-methyl-pyridine-2-sulphonic acid 2-(2-cyano-pyridin-4-yl)-6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-pyrimidin-4-ylamide there is obtained 5-methyl-pyridine-2-sulphonic acid 6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(2-1H-tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4-ylamide as a white substance of melting point 239-241 °C from CH3CN.
Example 30
In analogy to Example 3, from 5-isopropyl-pyridine-2-sulphonic acid 2-(2-cyano-pyridin-4-yl)-6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-pyrimidin-4-ylamide there is obtained 5-isopropyl-pyridine-2-sulphonic acid 6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(2-1H-tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4-ylamide as a white substance of melting point 198-200°C from acetonitrile. The corresponding disodium salt is obtained as a white powder from this product using sodium methylate in analogy to Example 5.
Example 31
In analogy to Example 3, from 4-tert-butyl-N-[5-(2-chloro-5-methoxy-phenoxy)-[2-(2-cyano-pyridin-4-yl]-6-(2-hydroxy-ethoxy)-pyrimidin-4-yl]-benzenesulphonamide there is obtained 4-tert-butyl-N-[5-(2-chloro-5-methoxy-phenoxy)-6-(2-hydroxy-ethoxy)-2-(2-1 H-tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4-yl]-

benzenesulphonamide of melting point 170-172°C from CH3CN. The corresponding disodium salt is obtained as a white powder from this product using sodium methylate in analogy to Example 5.
Example 32
In analogy to Example 3, from l,3-benzodioxol-5-sulphonic acid 5-(2-chloro-5-methoxy-phenoxy)-2-(2-cyano-pyridin-4-yl)-6-(2-hydroxy-ethoxy)-pyrimidin-4-yIamide there is obtained 1,3-benzodioxol-5-sulphonic acid [5-(2-chloro-5-methoxy-phenoxy)-6-(2-hydroxy-ethoxy)-2-(2-1H-tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4-yl]-amide.
Example 33
In analogy to Example 3, from 5-isopropyl-pyridine-2-sulphonic acid 5-(2-chloro-5-methoxy-phenoxy)-2-(2-cyano-pyridin-4-yl)-6-(2-hydroxy-ethoxy)-pyrimidin-4-ylamide there is obtained 5-isopropyl-pyridine-2-sulphonic acid [5-(2-chloro-5-methoxy-phenoxy)-6-(2-hydroxy-ethoxy)-2-(2-1H-tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4-yl]-amide.
Example 34
In analogy to Example 3, from 4-tert-butyl-N-[2-(6-cyano-pyridin-2-yl)-6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-pyrimidln-4-yl]-benzenesulphonamide there is obtained 4-tert-butyl-N-[6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-[6-(1 H-tetrazol-5-yl)-pyridin-2-yl]-pyrimidin-4-yl]-benzene-sulphonamide of melting point 248-251 °C (with decomposition) from CH2CI2 + CH3CN.
Example 35
In analogy to Example 4, from N-[6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(2-1H-tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4-yl]-benzenesulphonamide and 2-pyridyl-carbonyl

azide there is obtained 2-[5-(2-methoxy-phenoxy)-6-phenyl-sulphonylamino-2-(2-1 H-tetrazol-5-yi-pyridin-4-yi)-pyrimidin-4-yioxy]-ethyl pyridin-2-ylcarbamate as a white substance.
Example 36
In analogy to Example 4, from N-[6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(2-1H-tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4-yl]-4-methyl-benzenesulphonamide and 2-pyridyl-carbonyl azide there is obtained 2-[5-(2-methoxy-phenoxy)-6-(4-methyl-phenylsulphonylamino)-2-(2-1H-tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4-yloxy]-ethyl pyridin-2-ylcarbamate as a white substance of melting point 224-225°C from CH3CN.
Example 37
In analogy to Example 4, from N-[6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(2-1H-tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4-yl]-4-methy!-benzenesulphonamide and 3,4-methyl-enedioxy-phenyl-carbonyl azide there is obtained 2-[5-(2-methoxy-phenoxy)-6-(4-methylphenylsulphonylamino)-2-(2-1H-tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4-yloxy]-ethyl 1,3-benzo-dioxol-5-ylcarbamate of melting point 198-199°C from CH3CN.
Example 38
In analogy to Example 4, from N-[6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(2-1H-tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4-yl]-4-methoxy-benzenesulphonamide and 2-pyridyl-carbonyl azide there is obtained 2-[5-(2-methoxy-phenoxy)-6-(4-methoxy-phenylsuIphonylamino-2-(2-1H-tetrazol-5-yl-pyridin-2-yl)-pyrimidin-4-yloxy]-ethyl pyridin-2-ylcarbamate of melting point 224-225°C from EtOAc.
Example 39
In analogy to Example 4, from N-[6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(2-1H-tetrazol-5-yl-pyridin-4-yl)-

pyrimidin-4-yl]-4-methoxy-benzenesulphonamide and 3,4-methylenedioxy-phenylcarbonyl azide there is obtained 2-[5-(2-methoxy-phenoxy)-6-(4-methoxy-phenylsulphonylamino)-2-(2-1 H-tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4-yloxy]-ethyl 1,3-benzodioxol-5-ylcarbamate of melting point 198-200°C from EtOAc.
Example 40
In analogy to Example 4, from N-[6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(2-1 H-tetrazol-5-yl-pyrldln-4-yl)-pyrimidin-4-yl]-4-methylsulphanyl-benzenesulphonamide and 2-pyridylcarbonyl azide there is obtained 2-[5-(2-methoxy-phenoxy)-6-(4-methylsulphanylphenylsulphonylamino)-2-(2-1H-tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4-yloxy]-ethyl pyridin-2-ylcarbamate.
Example 41
In analogy to Example 4, from l,3-benzodioxol-5-sulphonic acid 6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(2-1 H-tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4-ylamide and 2-pyridyl-carbonyl azide there is obtained 2-[6-(1,3-benzodioxol-5-yl-sulphonylamino)-5-(2-methoxy-phenoxy)-2-(2-1H-tetra2ol-5-yl-pyridin-4-yl)-pyrimidin-4-yloxy]-ethyl pyridin-2-ylcarbamate of melting point 194-196°C from EtOAc.
Example 42
In analogy to Example 4, from l,3-benzodioxol-5-sulphonic acid 6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(2-l H-tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4-ylamide and 3,4-methylenmdioxy-phenyl-carbonyl azide there is obtained 2-[6-(l,3-benzodioxol-5-ylsulphonylamino)-5-(2-methoxy-phenoxy)-2-(2-l H-tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4-yloxy]-ethyl 1,3-benzodioxol-5-yIcarbamate of melting point 187-188°C from EtOAc.

Example 43
In analogy to Example 4, from N-[6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(2-l H-tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4-yl]-3,4-dimethoxy-benzenesulphonamide and 2-pyrldylcarbonyl azide there is obtained 2-[6-(3,4-dimethoxy-phenylsulphonylamino)-5-(2-methoxy-phenoxy)-2-(2-1H-tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4-yloxy]-ethyl pyridin-2-ylcarbamate.
Example 44
In analogy to Example 4, from N-[6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(2-l H-tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4-yl]-2,5-dimethoxy-benzenesulphonamide and 2-pyridylcarbonyl azide there is obtained 2-[5-(2-methoxy-phenoxy)-6-(2,5-dimethoxy-phenylsulphonylamino)-2-(2-1H-tetrazol-5-yl-pyridin-4-yl)-pyrimidin-2-yloxy]-ethyl pyridin-2-ylcarbamate.
Example 45
In analogy to Example 4, from pyridine-3-sulphonic acid 6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(2-l H-tetrazol-5-yl-pyrldin-4-yl)-pyrimidin-4-yIamide and 2-pyridylcarbonyl azide there is obtained 2-[5-(2-methoxy-phenoxy)-2-(2-1H-tetrazol-5-yl-pyridin-4-yl)-6-pyridin-3-ylsulphonylamino-pyrimidin4-yloxy]-ethyl pyridin-2-ylcarbamate.
Example 46
In analogy to Example 4, from pyridine-3-sulphonic acid 6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(2-1H-tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4-ylamide and 3,4-methylenedioxy-phenyl-carbonyl azide there is obtained 2-[5-(2-methoxy-phenoxy)-6-pyridin-3-ylsulphonylamino-2-(2-l H-tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4-yloxy]-ethyl 1,3-benzodioxol-5-ylcarbamate.

Example 47
In analogy to Example 4, from 5-methyl-pyrJdine-2-sulphonic acid 6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(2-1H-tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4-ylamide and 2-pyridyicarbonyl azide there is obtained 2-[5-(2-methoxy-phenoxy)-6-(5-methyl-pyridin-2-ylsulphonylamino)-2-(2-1H-tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4-yloxy]-ethyl pyridin-2-ylcarbamate.
Example 48
In analogy to Example 4 from 5-isopropyl-pyridine-2-sulphonic acid 6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(2-1H-tetrazol-5-yl-pyrldin-4-yl)-pyrimidin-4-ylamide and 2-pyridylcarbonyl azide there is obtained 2-[6-(5-isopropyl-pyridin-2-ylsulphonylamino)-5-(2-methoxy-phenoxy)-2-(2-1H-tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4-yloxy]-ethyl pyridin-2-ylcarbamate.
Example 49
In analogy to Example 4, from 5-isopropyl-pyridine-2-sulphonic acid 6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(2-1H-tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4-ylamide and 3,4-methylenedioxy-phenyl-carbonyl azide there is obtained 2-[6-(5-isopropyl-pyridin-2-ylsulphonylamlno)-5-(2-methoxy-phenoxy)-2-(2-l H-tetrazol-5-yl-pyridln-4-yl)-pyrimidin-4-yloxy]-ethyl 1,3-benzodioxol-5-ylcarbamate.
Example 50
In analogy to Example 4, from 4-tert-butyl-N-[5-(2-chloro-5-methoxy-phenoxy)-6-(2-hydroxy-ethoxy)-2-(2-1H-tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4-yl]-benzenesulphonamide and 2-pyridylcarbonyl azide there is obtained 2-[6-(4-tert-butyl-phenylsulphonylamino)-5-(2-chloro-5-methoxy-phenoxy)-2-(2-

1H-tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4-yloxy]-ethyl pyridin-2-yIcarbamate.
Example 51
In analogy to Example 4, from l,3-benzodioxol-5-sulphonic acid [5-(2-chloro-5-methoxy-phenoxy)-6-(2-hydroxy-ethoxy)-2-(2-1H-tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4-yl]-amide and 2-pyridylcarbonyl azide there is obtained 2-[6-(l,3-benzodioxol-5-ylsulphonylamino)-5-(2-chloro-5-methoxy-phenoxy)-2-(2-1H-tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4-yloxy]-ethyl pyridin-2-ylcarbamate.
Example 52
In analogy to Example 4, from 5-isopropyl-pyridine-2-sulphonic acid [5-(2-chloro-5-methoxy-phenoxy)-6-(2-hydroxy-ethoxy)-2-(2-l H-tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4-yl]-amide there is obtained 2-[5-(2-chloro-5-methoxy-phenoxy)-6-(5-isopropyl-pyridin-2-ylsulphonylamino]-2-(2-1H-tetrazol-5-yl-pyridin-2-yl)-pyrimidin-4-yloxy]-ethyl pyridin-2-yl-carbamate.
Example 53
In analogy to Example 4, from 4-tert-butyl-N-[6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-[6-(1H-tetrazol-5-yl)-pyridin-2-yl]-pyrimidin-4-yl]-benzenesuIphonamide there Is obtained 2-[6-(4-tert-butyl-phenylsulphonylamino)-5-(2-methoxy-phenoxy)-2-(2-1H-tetrazoI-5-yl-pyridin-2-yl)-pyrimidin-4-yloxy]-ethyl pyridin-2-ylcarbamate.
Example 54
In analogy to Example 1, from benzyloxy-ethanol Na with 4-[4-(4-tert-butyl-phenylsulphonylamino)-6-chloro-5-(2-methoxy-phenoxy)-pyrimidin-2-yl]-pyridine 1-oxide there is obtained N-[6-(2-benzyloxy-ethoxy)-5-(2-methoxy-phenoxy)-2-( 1 -oxy-

pyridin-4-yl)-pyrimidin-4-yl]-4-tert-butyl-ben2enesulphonamide of melting point 170-171 °C from CH3CN and therefrom with tri-methylsilyl cyanide in boiling triethylamine in analogy to Example 1, paragraph a), there is obtained N-[6-(2-benzyloxy-ethoxy)-2-(2-cyano-pyridin-4-yl)-5-(2-methoxy-phenoxy)-pyrimidin-4-yl]-4-tert-butyl-benzenesulphonamide.
Example 55
In analogy to Example 3, from N-[6-(2-ben2yloxy-ethoxy)-2-(2-cyano-pyridin-4-yl)-5-(2-methoxy-phenoxy)-pyrimidin-4-yl]-4-tert-butyl-ben2enesuIphonamide there is obtained N-[6-(2-benzyloxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(2-1H-tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4-yl]-4-tert-butyl-benzenesulphon-amide as an amorphous substance of melting point 173-175°C.
Example 56
In analogy to Example 1, from benzyloxy-ethanoi sodium and 5-methyl-pyridine-2-sulphonic acid 6-chIoro-5-(2-methoxy-phenoxy)-2-(1-oxy-pyridin-4-yl)-pyrimidin-4-ylamide there is obtained 5-methyl-pyridine-2-sulphonic acid [6-(2-benzyloxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(l-oxy-pyridin-4-yl)-pyrimidin-4-yl]-amide, melting point 206-208°C from CH3CN, and therefrom with trimethylsilyl cyanide in boiling triethylamine in analogy to Example 2 there is obtained the corresponding nitrile, 5-methylpyridine-2-sulphonic acid-N-[6-(2-benzyloxy-ethoxy)-2-(2-cyanopyridin-4-yl)-5-(2-methoxyphenoxy)-pyrimidin-4-yl]-amide.
Example 57
In analogy to Example 3, from the nitrile of Example 56 there is obtained 5-methyl-pyridine-2-sulphonic acid [6-(2-benzyloxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(2-1H-tetra2ol-5-yl-pyridin-4-yl]-amide, melting point 202-204°C from CH3CN.

Example 58
In analogy to Example 1, from benzyloxy-ethanol sodium and 5-isopropyl-pyridine-2-sulphonic acid 6-chloro-5-(2-methoxy-phenoxy)-2-(l-oxy-pyridin-4-yl)-pyrimidin-4-ylamide there is obtained 5-isopropyl-pyridine-2-sulphonic acid [6-(2-benzyloxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(1-oxy-pyridin-4-yl)-pyri-midin-4-yl]-amide and therefrom with trimethylsilyl cyanide in boiling triethylamine in analogy to Example 2 there is obtained the corresponding nitrile, 5-isopropylpyridine-2-sulphonic acid N-[6-(2-benzyloxy-ethoxy)-2-(2-cyanopyridin-4-yl)-5-(2-methoxyphenoxy)-pyrimidin-4-yl]-amide.
Example 59
In analogy to Example 3, from 4-isopropyl-N-[2-(2-cyano-pyridin-4-yl)-6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-pyrimidin-4-yl]benzenesulphonamide there is obtained 5-iso-propyl-pyridine-2-sulphonic acid [6-(2-benzyloxy-ethoxy)-5-(2-methoxy-phenoxy)-2-[2-(1H-tetrazol-5-yl)-pyridin-4-yl]-pyrimidin-4-yl]-amide of melting point 236-237°C from CH3CN.
Example 60
In analogy to Example 2, from 4-tert-butyl-N-[5-(2-methoxy-phenoxy)-2-(l-oxy-pyridin-4-yl)-6-[2-(tetrahydro-pyran-2-yloxy)-ethoxy]-pyrimidin-4-yl]-benzenesulphonamide with trimethylsilyl cyanide in triethylamine there is obtained 4-tert-butyl-N-[2-(2-cyano-pyridin-4-yl)-5-(2-methoxy-phenoxy)-6-[2-(tetrahydro-pyran-2-yl)-ethoxy]-pyrimidin-4-yl]-benzene-sulphonamide.
Example 61
In analogy to Example 3, from 4-tert-butyl-N-[2-(2-cyano-pyridin-4-yl)-5-(2-methoxy-phenoxy)-6-[2-(tetrahydro-pyran-2-yl)-ethoxy]-pyrimidin-4-yl]-benzenesulphonamide there is obtained 4-tert-butyl-N-[5-(2-methoxy-phenoxy)-6-[2-(tetra-

hydro-pyran-2-yIoxy)-ethoxy]-2-(2-1H-tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4-yl]-benzenesulphonamide.
Example 62
In analogy to Example 6, from 4-tert-butyl-N-[2-(2-cyano-pyridin-4-yl)-6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-pyrimidin-4-yl]-benzenesulphonamide there is obtained the coresponding iminoether and there from with NH4CI in CH3OH at room temperature there is obtained 4-tert-butyl-N-[2-[2-(amino-amino-methyl)-pyridin-4-yi]-6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-pyrimidin-4-yl]-benzenesulphonamide.
Example 63
In analogy to Example 6, from 4-tert-butyl-N-[2-(2-cyano-pyridin-4-yl)-6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-pyrimidin-4-yl]-benzenesulphonamide there is obtained the corresponding iminoether and there from with NHzOHHCI in CH3OH at room temperature there is obtained 4-tert-butyl-N-[2-[2-(hydroxyamino-imino-methyl)-pyridin-4-yl]-6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-pyrimidin-4-yl]-benzene-sulphonamide.
Example 64
In analogy to Example 6, from 4-tert-butyl-N-[2-(2-cyano-pyridin-4-yl)-6-(2-hydroxy-ethoxy)"5-(2-methoxy-phenoxy)-pyrimidin-4-yl]-benzenesulphonamide there is obtained the corresponding iminoether and therefrom with 3N HCI at room temperature there is obtained ethyl 4-[4-(4-tert-butyl-phenyl-sulphonylamino)-6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-pyrimidin-2-yl]-pyridine-2-carboxylate.
Example 65
By treating the ester prepared in Example 64 with 1N methanolic sodium hydroxide solution at room temperature and

acidifying the reaction solution with acetic acid there is obtained the corresponding 4-[4-(4-tert-butyl-phenylsulphonylamino)-6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-pyrimidin-2-yl]-pyridine-2-carboxylic acid.
Example 66
a) In analogy to Example 1, from 4-tert.-butyl-N-[6-chloro-2-(3-cyano-phenyl)-5-(2-methoxy-phenoxy)-pyrimidin-4-yl]-benzenesulphonamide and ethylene glycol sodium salt there is obtained 4-tert.-butyl-N-[2-(3-cyano-phenyl)-6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-pyrimidin-4-yl]-benzene-sulphonamide as a white product of melting point 197-198°C from EtOAc.
Preparation of the starting material:
In analogy to Example 1 b), from 1,3-dicyanobenzene and sodium methylate in methanol followed by ammonium chloride there is obtained 3-cyano-benzamidine hydrochloride and therefrom with diethyl (2-methoxy-phenoxy)malonate there is obtained rac.-3-[5-(2-methoxy-phenoxy)-4,6-dioxo-l ,4,5,6-tetrahydro-pyrimidin-2-yl]-benzonitrile as a white product. From this compound with PCI5 and POCI3 there is obtained 3-[4,6-dichloro-5-(2-methoxy-phenoxy)-pyrimidin-2-yl]-benzonitrile with a melting point of 155-156° from EtOAc. Reaction with 4-tert.-butylbenzenesulphonamide K yields 4-tert.-butyl-N-[6-chloro-2-(3-cyanophenyl)-5-(2-methoxyphenoxy)-pyrimidin-4-yl]-benzenesulphonamide.
Example 67
In analogy to Example 3, from 4-tert.-butyl-N-[2-(3-cyano-phenyl)-6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-pyri-midin-4-yl]-benzenesulphonamide, sodium azide and ammonium chloride in DMF there is obtained 4-tert.-butyl-N-[6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(3-1H-tetrazol-5-yl-phenyl)-pyrimidin-4-yl]-benzenesulphonamide as a solid.

Example 68
in analogy to Example 4, from 4-tert.-butyl-N-[6-(2-
hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(3-1H-tetrazol-5-yl-phenyl)-pyrimidin-4-yl]-benzenesulphonamide and a-pyridyl-
carbonyl azide there is obtained 2-[6-(4-tert.-butyl-phenyl-sulphonyl)-5-(2-methoxy-phenoxy)-2-(3-1H-tetrazol-5-yl-phenyl)-pyrimidin-4-yloxy]-ethyl pyridin-2-ylcarbamate of melting point 138-139°C.
Example 69
In analogy to Example 1, from 4-tert.-butyl-N-[6-chloro-2-(3-cyano-phenyl)-5-(2-methoxy-phenoxy)-pyrimidin-4-yl]-benzenesulphonamide and benzyloxy-ethanol sodium salt there is obtained N-[6-(2-benzyloxy-ethoxy)-2-(3-cyano-phenyl)-5-(2-methoxy-phenoxy)-pyrimidin-4-yl]-4-tert.-butyr-benzene-sulphonamide as a solid material of melting point 120-122°C from EtOAc.
Example 70
In analogy to Example 3, from N-[6-(2-benzyloxy-ethoxy)-2-(3-cyano-phenyl)-5-(2-methoxy-phenoxy)-pyrimidin-4-yl]-4-tert.-butyl-benzenesulphonamide, sodium azide and ammonium chloride in DMF there is obtained N-[6-(2-benzyloxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(3-1H-tetrazol-5-yl-phenyl)-pyrimidin-4-yl]-4-tert.-butyl-benzenesulphonamide as a lighy yellow foam.
Example 71
In analogy to Example 1, from 4-tert.-butyl-N-[6-chloro-2-(4-cyano-phenyl)-5-(2-methoxy-phenoxy)-pyrimidin-4-yl]-benzenesulphonamide and ethylene glycol sodium salt there is obtained 4-tert.-butyl-N-[2-(4-cyano-phenyl)-6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-pyrimidin-4-yl]-benzene-

sulphonamide as a light brownish material of melting point 169-170°C from EtOAc.
Preparation of the starting material:
From 1,4-dicyanobenzene and sodium methylate in methanol followed by ammonium chloride there is obtained 4-cyano-benz-amidine hydrochloride, which is used in the next step without further purification, and therefrom with diethyl (2-methoxy-phenoxy)-malonate there is obtained rac.-4-[5-(2-methoxy-phenoxy)-4,6-dioxo-1,4,5,6-tetrahydro-pyrimidin-2-yl]-benzo-nitrile as a yellow product with a melting point >250oC. With PCI5 and POCI3 this compound yields 4-[4,6-dichloro-5-(2-methoxy-phenoxy)-pyrimidin-2-yl]-benzonitrile as a brownish material of melting point 179-180°C from EtOAc. Reaction with 4-tert.-butyl-benzenesuIphonamide K finally yields 4-tert.-butyl-N-[6-chIoro-2-(4-cyanophenyl)-5-(2-methoxy-phenoxy)-pyrimidin-4-yl]-benzenesulphonamide.
Example 72
In analogy to Example 3, from 4-tert.-butyl-N-[2-(4-cyano-phenyl)-6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-pyrim-idin-4-yl]-benzenesulphonamide, sodium azide and ammonium chloride in DMF there is obtained 4-tert.-butyl-N-[6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(4-1H-tetrazol-5-yl-phenyl)-pyrimidin-4-yl]-benzenesulphonamide as a white material.
Example 73
In analogy to Example 1, from 4-tert.-butyl-N-[6-chloro-2-(4-cyano-phenyl)-5-(2-methoxy-phenoxy)-pyrimidin-4-yl]-benzenesulphonamide with benzyloxyethanol sodium salt there is obtained N-[6-(2-benzyloxy-ethoxy)-2-(4-cyano-phenyl)-5-(2-methoxy-phenoxy)-pyrimidin-4-yl]-4-tert.-butyl-benzene-sulphonamide of melting point 158-159°C from EtOAc.

Example 74
In analogy to Example 3, from N-[6-(2-benzyloxy-ethoxy)-2-(4-cyano-phenyl)-5-(2-methoxy-phenoxy)-pyrimidin-4-yl]-4-tert.-butyl-benzenesulphonamide, sodium azide and ammonium chloride in DMF there is obtained N-[6-(2-benzyloxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(4-1H-tetrazol-5-yl-phenyl)-pyrimidin-4-yl]-4-tert.-butyl-benzenesulphonamide as a foam.
Example 75
a) A solution of 2.1 g (3.4 mmol) of 4-tert.-butyl-N-[6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(2-1H-tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4-yl]-benzenesulphonamide in 40 ml of abs. THF is treated with 2 ml of l-(tert.-butyl-dimethylsilyl)-imidazole and heated to 50° while stirring for one hour. The solution is evaporated under reduced pressure and the residue is recrystallized from methylene chloride and isopropyl ether. There is thus obtained 4-tert.-butyl-N-[6-[2-(tert.-butyl-dimethyl-silanyloxy)-ethoxy]-5-(2-methoxy-phenoxy)-2-(2-1H-tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4-yl]-benzenesulphona-mide of melting point 237-239°C with decomposition.
b) A solution of 366.5 mg (0.5 mmol) of 4-tert.-butyl-N-[6-[2-tert.-butyl-dimethyl-siIanyloxy)-ethoxy]-5-(2-methoxy-phenoxy)-2-(2-1H-tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4-yl]-benzenesulphonamide in 30 ml of abs. THF is treated at room temperature with 112.2 mg (1 mmol) of potassium tert.-butylate and the suspension is heated at 40°C while stirring for 30 min. 1 ml of ethyl bromide is added to the clear solution and the solution is heated at 40°C for 4 days. Thereafter, the solution is evaporated under reduced pressure, the residue is taken up in a 1:1 mixture of methylene chloride and ether and the organic solution is washed three times with 0.5N NaHCO3 and thereafter with water. The organic extracts are dried with sodium sulphate and evaporated under reduced pressure. The residue is chromatographed on silica gel with cyclohexane-EtOAc 1:1. Firstly there are isolated 100 mg of 4-tert.-butyl-N-[6-[2-

(tert.-butyl-dimethyl-siIanyloxy)-ethoxy-2-[2-(2-ethyl-2H-
tetrazol-5-yl)-pyridin-4-yl]-5-(2-methoxy-phenoxy)-pyrimidin-
4-yl]-benzenesulphonamide and thereafter 100 mg of 4-tert.-
butyl-N-[6-[2-(tert.-butyl-dimethyl-silanyloxy)-2-[2-(1-ethyl-
1H-tetrazol-5-yl)-pyridin-4-yl]-5-(2-methoxy-phenoxy)-
pyrimidin-4-yl]-benzenesulphonamide.
c) A solution of 90 mg of 4-tert.-butyl-N-[6-[2-(tert.-butyl-dimethyl-silanyloxy)-ethoxy-2-[2-(2-ethyl-2H-tetrazol-5-yl)-pyridin-4-yl]-5-(2-methoxy-phenoxy)-pyrimidin-4-yl]-benzene-sulphonamide in 4 ml of CH3CN-H20 1:1 is treated with 5 drops of trifluoroacetic acid and left at room temperature for 24 hours. Thereafter, acetonitrile is evaporated at 30°C under reduced pressure and the aqueous phase is treated firstly with 1N NaOH, then with glacial acetic acid to pH 4 and extracted with ether. The organic extracts are washed with H2O, dried with sodium sulphate and evaporated under reduced pressure. There is thus obtained 4-tert.butyl-N-[2-[2-(2-ethyl-2H-tetrazol-5-yl)-pyridin-4-yl]-6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-pyrimidin-4-yl]benzenesulphonamide as a yellowish foam. Analogously, from 4-tert.-butyl-N-[6-[2-(tert.-butyl-dimethyl-silanyloxy)-2-[2-(l-ethyl-1H-tetrazol-5-yl)-pyridin-4-yl]-5-(2-methoxy-phenoxy)-pyrimldin-4-yl]-benzenesulphonamide there is obtained 4-tert.butyI-N-[2-[2-(l-ethyl-1 H-tetrazol-5-yl)-pyridin-4-yl]-6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-
pyrimidin-4-yl]benzenesulphonamide as a yellowish foam.

Example A
Tablets containing the following ingredients can be produced in a conventional manner:
Ingredients Per tablet
Compound of formula I 10.0 -100.0 mg
Lactose 125.0mg
Corn starch 75.0 mg
Talc 4.0 mg
Magnesium stearate 1.0 mg
Example B
Capsules containing the following ingredients can be produced in a conventional manner:
Ingredients Per Capsule
Compound of formula I 25.0 mg
Lactose 150.0 mg
Corn starch 20.0 mg
Talc 5.0 mg
Example C
Injection solutions can have the following composition:
a) Compound of formula I, e.g.
4-tert.butyl-N-[6-(2-hydroxy-ethoxy)-5-
(2-methoxy-phenoxy)-2-(2-1H-tetra2ol-
5-yl)-pyridin-4-yl]-pyrimidin-4-yl]-
benzenesulphonamide disodium salt 3.0 mg
Gelatine 150.0mg
Water for injection solutions ad 1.0 ml

b) Compound of formula I, e.g. 5-methyl-pyricline-2-sulphonic acid 6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(2-1H-tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4-ylamide disodium salt 5.0 mg Gelatine 150.0mg Water for injection solutions ad 1.0 ml
c) Compound of formula I, e.g. 5-isopropyl-pyridine-2-suIphonic acid 6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(2-1H-tetra2ol-5-yl-pyridin-4-yl)-pyrimidin-4-ylamide disodium salt 5.0 mg Gelatine 150.0mg Water for injection solutions ad 1.0 ml
Example D
500 mg of compound of formula I are suspended in 3.5 ml of Myglyol 812 and 0.08 g of benzyl alcohol. This suspension is filled into a container having a dosage valve. 5.0 g of Freon 12 are filled into the container under pressure through the valve. The Freon is dissolved in the Myglyol-benzyl alcohol mixture by shaking. This spray container contains about 100 single doses which can be applied individually.











We claim:
1. Compounds of the formula

wherein
R1 signifies aryl or heterocyclyl;
R2 signifies tetrazolyl, lower-alkyl-substituted
tetrazolyl, cyano, carboxy, lower-alkoxycarbonyl,
hydroxymethyl, formyl, carbamoyl, thiocarbamoyl,
amidino or hydroxyamidino;
R3 signifies a residue -O-(CRaRb)n-OR9;
R4-R8 signify hydrogen, lower-alkoxy or halogen;
R9 signifies hydrogen, aryl, iower-aralkyl, heterocyclyl
or a residue -C(0)NHR10;
R10 signifies lower-alkyl, phenyl, substituted phenyl,
pyridyl or substituted pyridyl;
Ra and Rb signify hydrogen or lower-alkyl;
n signifies 2, 3 or 4; and
A and B signify CH; or one of the symbols A or B signifies
nitrogen and the other signifies CH; or
R2 signifies hydrogen and one of the symbols A or B
signifies N-oxide (N-O) and the other signifies CH,
and pharmaceutically usable salts of compounds of formula I.
2. Compounds according to claim 1, in which R9 signifies hydrogen, benzyl, ring-substituted benzyl or a residue -C(0)NHR10 and the remaining symbols have the significance set forth in claim 1.
3. Compounds according to claim 1 or claim 2, in which A and B are CH.

4. Compounds according to claim 1 or claim 2, in which one of the symbols A or B is nitrogen.
5. Compounds according to claim 1 or claim 2, in which A is nitrogen and B is CH.
6. Compounds according to any one of claims 1-5, in which R2 is a tetrazolyl residue.
7. Compounds according to any one of claims 1 -6, in which iS a phenyl residue, which is mono- or di-substituted, or a pyridyl residue, which is mono-substituted by alkyl, R3 is -0(CH2)nOH, -0(CH2)nO-benzyl or -0(CH2)nOC(0)NHRlO and n is 2.
8. Compounds according to any one of claims 1 -7, in which R4 is lower-alkoxy and R5-R8 are hydrogen; or R4 is halogen, R7 is lower-alkoxy and R5, R6 and R8 are hydrogen.
9. The compounds according to claim 6,
5-methyl-pyridine-2-sulphonic acid 6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(2-1H-tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4-ylamide,
5-isopropyl-pyridine-2-sulphonic acid 6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(2-1H-tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4-ylamide.
10. The compounds according to claim 6,
4-tert-butyl-N-[6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(2-1 H-tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4-yl]-benzenesulphonamide,
2-[6-(4-tert-butyI-phenylsulphonylamino)-5-(2-methoxy-phenoxy)-2-(2-1H-tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4-yl-oxy]-ethyl pyridin-2-ylcarbamate,
N-[6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(2-1H-tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4-yl]-benzenesulphon-amide.

N-[6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(2-1H-
tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4-yl]-4-methyl-benzene-sulphonamide,
N-[6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(2-1H-tetrazol-5-yl-pyridin-4-yI)-pyrimidin-4-yl]-4-nnethoxy-benzenesulphonamide,
N-[6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(2-1H-tetrazol-S-yl-pyridin-4-yl)-pyrimidin-4-yl]-4-methylsulphanyl-benzenesulphonamide,
1,3-benzodioxol-5-sulphonic acid 6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(2-1H-tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4-ylamide,
N-[6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(2-1H-tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4-yl]-3,4-dimethoxy-benzenesulphonamide,
N-[6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(2-1H-tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4-yl]-2,5-dimethoxy-benzolsulphonamide,
pyridine-3-sulphonic acid 6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(2-1 H-tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4-ylamide,
4-tert-butyl-N-[5-(2-chloro-5-methoxy-phenoxy)-6-(2-hydroxy-ethoxy)-2-(2-l H-tetrazol-5-yi-pyridin-4-yl)-pyrimidin-4-yl]-benzenesuiphonamide,
1,3-benzodioxol-5-sulphonic acid [5-(2-chloro-5-methoxy-phenoxy)-6-(2-hydroxy-ethoxy)-2-(2-1H-tetrazoi-5-yl-pyridin-4-yl)-pyrimidin-4-yl]-amide,
5-isopropyl-pyridine-2-sulphonic acid [5-(2-chloro-5-methoxy-phenoxy)-6-(2-hydroxy-ethoxy)-2-(2-1H-tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4-yI]-amide,
4-tert-butyl-N-[6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-[6-(1H-tetrazol-5-yl)-pyridin-2-yl]-pyrimidin-4-yl]-
benzenesulphonamide,
2-[5-(2-methoxy-phenoxy)-6-phenylsulphonylamino-2-(2-
1H-tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4-yloxy]-ethyl
pyridin-2-ylcarbamate,
2-[5-(2-methoxy-phenoxy)-6-(4-methyl-phenyIsulphonyl-
amino)-2-(2-1 H-tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4-

yloxy]-ethyl pyridin-2-yIcarbamate,
2-[5-(2-methoxy-phenoxy)-6-(4-methyl-phenylsulphonyl-amino)-2-(2-1H-tetrazol-5-yl-pyridin-4-yI)-pyrimidin-4-yloxy]-ethyl 1,3-benzodioxol-5-ylcarbamate,
2-[5-(2-methoxy-phenoxy)-6-(4-methoxy-phenylsulphonyl-amino-2-(2-1H-tetrazol-5-yl-pyridin-2-yl)-pyrimidin-4-yloxy]-ethyl pyridin-2-ylcarbamate,
2-[5-(2-methoxy-phenoxy)-6-(4-methoxy-phenylsulphonyl-amino)-2-(2-1H-tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4-yloxy]-ethyl 1,3-benzodioxol-5-ylcarbamate,
2-[5-(2-methoxy-phenoxy)-6-(4-methylsulphanylphenyl-sulphonylamino)-2-(2-1H-tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4-yIoxy]-ethyl pyridin-2-ylcarbamate
2-[6-(1,3-benzodioxol-5-ylsuIphonylamino)-5-(2-methoxy-phenoxy)-2-(2-1 H-tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4-yIoxy]-ethyl pyridin-2-yIcarbamate,
2-[6-(1,3-benzodioxol-5-yIsulphonylamino)-5-(2-methoxy-phenoxy)-2-(2-l H-tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4-yloxy]-ethyl 1,3-benzodioxol-5-ylcarbamate,
2-[6-(3,4-dimethoxy-phenylsulphonylamino)-5-(2-methoxy-phenoxy)-2-(2-1H-tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4-yloxy]-ethyl pyridin-2-ylcarbamate,
2-[5-(2-methoxy-phenoxy)-6-(2,5-dimethoxy-phenyl-sulphonyIamino)-2-(2-1 H-tetrazol-5-yl-pyridin-4-yl)-pyrimidin-2-yIoxy]-ethyl pyridin-2-ylcarbamate,
2-[5-(2-methoxy-phenoxy)-2-(2-l H-tetrazol-5-yl-pyridin-4-yl)-6-pyridin-3-ylsulphonylamino-pyrimidin4-yloxy]-ethyl pyridin-2-ylcarbamate,
2-[5-(2-methoxy-phenoxy)-6-pyridin-3-ylsulphonylamino-2-(2-l H-tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4-yloxy]-ethyl 1,3-ben2odioxol-5-ylcarbamate,
2-[5-(2-methoxy-phenoxy)-6-(5-methyl-pyridin-2-yl-sulphonylamino)-2-(2-l H-tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4-yloxy]-ethyl pyridin-2-ylcarbamate,
2-[6-(5-isopropyl-pyridin-2-ylsulphonylamino)-5-(2-methoxy-phenoxy)-2-(2-1H-tetrazoI-5-yl-pyridin-4-yl)-pyrimidin-4-yloxy]-ethyl pyridin-2-ylcarbamate
2-[6-(5-isopropyl-pyridin-2-ylsulphonylamino)-5-(2-

methoxy-phenoxy)-2-(2-1H-tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4-yIoxy]-ethyl 1,3-benzodioxol-5-ylcarbamate,
2-[6-(4-tert-butyl-phenylsulphonylamino)-5-(2-chloro-5-methoxy-phenoxy)-2-(2-1H-tetrazol-5-yl-pyridin-4-yI)-pyrimidin-4-yloxy]-ethyl pyridin-2-ylcarbamate,
2-[6-(l,3-benzodioxol-5-ylsulphonylamino)-5-(2-chloro-5-methoxy-phenoxy)-2-(2-1H-tetrazoI-5-yl-pyridin-4-yl)-pyrinnidin-4-yloxy]-ethyl pyridin-2-ylcarbamate,
2-[5-(2-chloro-5-methoxy-phenoxy)-6-(5-isopropyl-pyridin-2-ylsulphonylamino]-2-(2-1H-tetrazol-5-yl-pyridin-2-yl)-pyrimidin-4-yloxy]-ethyl pyridin-2-ylcarbamate,
2-[6-(4-tert-butyl-phenyIsulphonylamino)-5-(2-methoxy-phenoxy)-2-(2-1 H-tetrazol-5-yl-pyridin-2-yl)-pyrimidin-4-yloxy]-ethyl pyridin-2-ylcarbamate,
N-[6-(2-benzyloxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(2-1 H-tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4-yl]-4-tert-butyl-benzenesulphonamide,
5-methyl-pyridine-2-sulphonic acid [6-(2-benzyloxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(2-1H-tetrazol-5-yl-pyridin-4-yl]-amide,
5-isopropyl-pyridine-2-sulphonic acid [6-(2-benzyloxy-ethoxy)-5-(2-methoxy-phenoxy)-2-[2-(1H-tetrazol-5-yl)-pyridin-4-yl]-pyrimidin-4-yi]-amide,
4-tert-butyl-N-[5-(2-methoxy-plienoxy)-6-[2-(tetrahydro-pyran-2-yloxy)-ethoxy]-2-(2-1H-tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4-yl]-benzenesulphonamide,
4-tert.butyl-N-[2-[2-(l -ethyl-1 H-tetrazol-5-yl)-pyridin-4-yl]-6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-pyrimidin-4-yl]benzenesulphonamide.
11. The compounds according to claim 2,
4-tert.-butyl-N-[2-(3-cyano-phenyl)-6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-pyrimidin-4-yl]-benzenesulphonamide,
4-tert.-butyl-N-[6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(3-1H-tetrazoI-5-yl-phenyl)-pyrimidin-4-yl]-benzenesulphonamide,

2-[6-(4-tert.-butyl-phenyIsulphonyl)-5-(2-methoxy-phenoxy)-2-(3-1H-tetrazol-5-yl-phenyl)-pyrimidin-4-yloxy]-ethyl pyridin-2-yIcarbamate,
N-[6-(2-benzyloxy-ethoxy)-2-(3-cyano-phenyl)-5-(2-methoxy-phenoxy)-pyrimidin-4-yl]-4-tert.-butyl-benzenesulphonamide,
N-[6-(2-benzyloxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(3-1 H-tetrazol-5-yl-phenyl)-pyrimidin-4-yl]-4-tert.-butyl-benzenesulphonamide,
4-tert.-butyl-N-[2-(4-cyano-phenyl)-6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-pyrimidin-4-yl]-benzene-sulphonamid,
4-tert.-butyl-N-[6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(4-l H-tetrazol-5-yl-phenyl)-pyrimidin-4-yl]-benzenesulphonamide,
N-[6-(2-benzyloxy-ethoxy)-2-(4-cyano-phenyi)-5-(2-methoxy-phenoxy)-pyrimidin-4-yl]-4-tert.-butyl-benzene-sulphonamide,
N-[6-(2-benzyloxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(4-1H-tetrazol-5-yl-phenyl)-pyrimidin-4-yl]-4-tert.-butyl-benzenesulphonamide.
12. The compounds according to claim 3,
4-tert-butyl-N-[2-(2-cyano-pyridin-4-yl)-6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-pyrimidin-4-yl]-benzenesulphonamide,
N-[2-(2-cyano-pyridin-4-yl)-6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-pyrimidin-4-yl]-benzenesulphonamide,
N-[2-(2-cyano-pyridin-4-yl)-6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-pyrimidin-4-yI]-4-methyl-ben2ene-sulphonamide,
N-[2-(2-cyano-pyridin-4-yi)-6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-pyrimidin-4-yl]-4-methoxy-benzene-sulphonamide,
N-[2-(2-cyano-pyridin-4-yl)-6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-pyrimidin-4-yl]-4-methylsulphanyi-ben2ene-sulphonamide,

l,3-benzodioxol-5-sulphonic acid 2-(2-cyano-pyridin-4-
yl)-6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-pyrimidin-4-ylamide,
N-[2-(2-cyano-pyridin-4-yl)-6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-pyrimidin-4-yl]-3,4-dimethoxy-benzene-sulphonamide,
N-[2-(2-cyano-pyridin-4-yl)-6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-pyrimidin-4-yl]-2,5-dimethoxy-benzene-sulphonamide,
pyridine-3-sulphonic acid 2-(2-cyano-pyridin-4-yl)-6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-pyrimidin-4-ylamide,
5-metliyi-pyridine-2-suiphonic acid 2-(2-cyano-pyridin-4-yl)-6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-pyrimidin-4-ylamide,
5-isopropyl-pyridine-2-sulphonic acid 2-(2-cyano-pyridin-4-yl)-6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-pyrimidin-4-yIamide,
4-tert-butyl-N-[5-(2-chloro-5-methoxy-phenoxy)-2-(2-cyano-pyridin-4-yl)-6-(2-hydroxy-ethoxy)-pyrimidin-4-yl]-benzenesulphonamide,
1,3-benzodioxol-5-sulphonic acid 5-(2-chloro-5-methoxy-phenoxy)-2-(2-cyano-pyridin-4-yl)-6-(2-hydroxy-ethoxy)-pyrimidin-4-ylamide,
5-isopropyl-pyridine-2-sulphonic acid 5-(2-chloro-5-methoxy-phenoxy)-2-(2-cyano-pyridin-4-yl)-6-(2-hydroxy-
ethoxy)-pyrimidin-4-ylamide,
4-tert-butyl-N-[2-(6-cyano-pyridin-2-yl)-6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-pyrimidin-4-yl]-benzene-
sulphonamide,
N-[6-(2-benzyloxy-ethoxy)-2-(2-cyano-pyridin-4-yi)-5-(2-methoxy-phenoxy)-pyrimidin-4-yl]-4-tert-butyi-benzenesulphon-amide,
5-isopropyi-pyridine-2-sulphonic acid-N-[6-(2-benzyloxy-ethoxy)-2-(2-cyanopyridin-4-yl)-5-(2-methoxyphenoxy)-pyrimidin-4-yl]-amide,
4-tert-butyl-N-[2-(2-cyano-pyridin-4-yl)-5-(2-methoxy-phenoxy)-6-[2-(tetrahydro-pyran-2-yl)-ethoxy]-pyrimidin-4-yl]-benzenesulphonamide,

4-tert-butyl-N-[2-[2-(amino-imino-methyl)-pyridin-4-yl]-6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-pyrimidin-4-yl]-benzenesulphonamide,
4-tert-butyl-N-[2-[2-(hydroxyamino-imino-methyI)-pyridin-4-yl]-6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-pyrimidin-4-yl]-benzenesulphonamide,
ethyl 4-[4-(4-tert-butyl-phenylsulphonylamino)-6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-pyrimidin-2-yl]-pyridine-2-carboxylate,
4-[4-(4-tert-butyl-phenylsulphonylamino)-6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-pyrimidin-2-yl]-pyridine-2-carboxylic acid.
13. The compounds according to claim 1,
4-[4-(4-tert-butyl-phenylsulphonylamino)-6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-pyrimidin-2-yl]-pyridlne 1 -
oxide,
N-[6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(l-oxy-pyridin-4-yl)-pyrimidin-4-yl]-benzenesulphonamide,
N-[6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(l-oxy-pyridin-4-yl)-pyrimidin-4-yl]-4-methyl-benzene-
sulphonamide,
N-[6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(l-oxy-pyridin-4-yI)-pyrimidin-4-yl]-4-methoxy-benzene-
sulphonamide,
N-[6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(l-
oxy-pyridin-4-yl)-pyrimidin-4-yl]-4-methylsulphanyl-benzenesulphonamide,
l,3-benzodioxol-5-sulphonic acid 6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(1-oxy-pyridin-4-yl)-pyrimidin-4-
ylamide,
N-[6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(1-
oxy-pyridin-4-yl)-pyrimidin-4-yl]-3,4-dimethoxy-benzene-sulphonamide,
N-[6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(l-oxy-pyridin-4-yl)-pyrimidin-4-yl]-2,5-dimethoxy-benzene-sulphonamide,

pyridine-3-sulphonic acid 6-(2-hydroxy-ethoxy)-5-(2-
methoxy-phenoxy)-2-(1-oxy-pyridin-4-yl)-pyrimidin-4-ylamide, 5-methyl-pyridine-2-sulphonic acid 6-(2-hydroxy-ethoxy)-
5-(2-methoxy-phenoxy)-2-(1-oxy-pyridin-4-yl)-pyrimidin-4-ylamide,
5-isopropyl-pyridine-2-sulphonic acid 6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(l-oxy-pyridin-4-yl)-pyrimidin-4-ylamide,
4-tert-butyl-N-[5-(2-chloro-5-methoxy-phenoxy)-6-(2-hydroxy-ethoxy)-2-(l-oxy-pyridin-4-yl)-pyrimidin-4-yl]-benzenesulphonamide,
l,3-benzodioxol-4-sulphonic acid 5-(2-chloro-5-methoxy-phenoxy)-6-(2-hydroxy-ethoxy)-2-(l-oxy-pyridin-4-yl)-pyrimidin-4-ylamide,
5-isopropyl-pyridine-2-sulphonic acid 5-(2-chloro-5-methoxy-phenoxy)-6-(2-hydroxy-ethoxy)-2-(l-oxy-pyridin-4-
yl)-pyrimidin-4-ylamide,
2-[4-(4-tert-butyl-phenylsuIphonylamino)-6-(2-hydroxy-
ethoxy)-5-(2-rnethoxy-phenoxy)-pyrimidin-2-yl]-pyridine 1 -
oxide.
14, Pharmaceutical preparations, especially for the
treatment of disorders which are associated with endothelin
activities, especially circulatory disorders such as hypertension,
ischaemia, vasospasms and angina pectoris, containing a
compound of any one of claims 1-13 and usual carrier materials
and adjuvants.
15. A process for the manufacture of compounds of any
one of claims 1-13, which process comprises


wherein R12 is 3. or 4-cyanophenyl or 2- or 4-pyridyl N-oxide and Hal is halogen and the remaining symbols have the significance set forth above, with a compound of the formula MO-(CRaRb)n-OR91, wherein M Is an alkali metal and R91 is hydrogen, aryl, lower-aralkyl or heterocyclyl and Ra, Rb and n have the significance set forth above; or

wherein R11 is 2- or 4-pyridyl N-oxide and the remaining symbols have the significance set forth above, with a trialkylsilyl cyanide and a trialkylamine; or
c) reacting a compound of formula I in which R2 is cyano and
the remaining symbols have the significance set forth above with
an azide in the presence of an aprotic Lewis acid; or
d) converting a compound of formula I in which R2 is cyano and
the remaining symbols have the significance set forth above with
an alkali metal alcoholate and thereafter with hydrazine into the
corresponding amidrazone and treating this with a nitrite and an
acid; or
e) reacting a compound of formula I in which R9 is hydrogen with an isocyanate of the formula RIONCO; or
f) transforming the cyano group in a compound of formula I in which R2 is cyano and the remaining symbols have the significance set forth above into an amidino, carbamoyl, thiocarbamoyl, lower-alkoxycarbonyl, carboxy, hydroxymethyl, formyl or hydroxyamidino group; or

g) alkylating the tetrazolyl group in a compound of formula I in which R2 is tetrazolyl and R9 is a hydroxy protecting group, benzyl or ring-substituted benzyl and cleaving off a hydroxyl protecting group from the reaction product;
and, if desired, converting a compound of formula I obtained into a salt.
16. The compounds of any one of claims 1-13 for use as medicaments, especially for the treatment of disorders which are associated with endothelln activities, especially circulatory disorders such as hypertension, ischaemia, vasospasms and angina pectoris.
17. The use of compounds of any one of claims 1-13 as active ingredients for the production of medicaments for the treatment of disorders which are associated with endothelin activities, especially circulatory disorders such as hypertension, ischaemia, vasospasms and angina pectoris.
18. The invention as hereinbefore described.


19. Compounds substantially as hereinbefore described with reference to the Examples.
20. A process for the manufacture of compounds substantially as hereinbefore described with reference to the Examples.


Documents:

1425-mas-1995 abstract-duplicate.tif

1425-mas-1995 form-2.tif

1425-mas-1995 petition.tif

1425-mas-1995-abstract.pdf

1425-mas-1995-claims filed.pdf

1425-mas-1995-claims granted.pdf

1425-mas-1995-correspondnece-others.pdf

1425-mas-1995-correspondnece-po.pdf

1425-mas-1995-description(complete)filed.pdf

1425-mas-1995-description(complete)granted.pdf

1425-mas-1995-form 1.pdf

1425-mas-1995-form 13.pdf

1425-mas-1995-form 18.pdf

1425-mas-1995-form 26.pdf

1425-mas-1995-form 4.pdf

1425-mas-1995-other documents.pdf

1425.jpg


Patent Number 211748
Indian Patent Application Number 1425/MAS/1995
PG Journal Number 52/2007
Publication Date 28-Dec-2007
Grant Date 09-Nov-2007
Date of Filing 02-Nov-1995
Name of Patentee M/S. F HOFFMANN LA ROCHE AG
Applicant Address 124 GRENZACHERSTRASSE, CH-4070 BASEL,
Inventors:
# Inventor's Name Inventor's Address
1 VOLKER BUREU., ET.AL., 7 BELCHENSTRASSE, D-79418 SCHLIENGEN,
PCT International Classification Number C07C 311/08
PCT International Application Number N/A
PCT International Filing date
PCT Conventions:
# PCT Application Number Date of Convention Priority Country
1 3837/94 1994-12-20 Switzerland
2 2419/95 1995-08-24 Switzerland